Latest On Clinuvel Pharmaceuticals Limited (CLVLY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-09-07 06:09 EST | Dividend | A dividend of $0.03 has been announced on Aug 29, 2023. It will be paid Oct 2, 2023 with an ex-dividend date of Sep 7, 2023. | Neutral |  |
| 2022-09-09 06:08 EST | Dividend | A dividend of $0.03 has been announced on Aug 31, 2022. It will be paid Oct 3, 2022 with an ex-dividend date of Sep 9, 2022. | Neutral | |
| 2022-02-25 02:41 EST | News | Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-23 11:02 EST | News | Clinuvel Pharmaceuticals reports 1H results | N/A | |
| 2021-09-03 06:13 EST | Dividend | A dividend of $0.02 has been announced on Aug 27, 2021. It will be paid Sep 27, 2021 with an ex-dividend date of Sep 3, 2021. | Neutral | |
| 2021-02-26 09:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 18:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 23:44 EST | News | Clinuvel: Stroke And DNA Repair Unlock Large New Markets | N/A | |
| 2020-11-07 19:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-04 06:08 EST | Dividend | A dividend of $0.02 has been announced on Aug 27, 2020. It will be paid Sep 28, 2020 with an ex-dividend date of Sep 4, 2020. | Neutral | |
| 2020-08-31 08:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-28 06:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 01:10 EST | News | Clinuvel Pharmaceuticals - Conservative Valuation Estimation Indicates Significant Upside | N/A | |
| 2020-05-07 03:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 10:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 07:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 03:17 EST | Financials | Company financials have been released. | Neutral | |
About Clinuvel Pharmaceuticals Limited (CLVLY):
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
General
- Name Clinuvel Pharmaceuticals Limited
- Symbol CLVLY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndJune
- Web URLhttp://www.clinuvel.com
View More
Valuation
- Trailing PE 107.45
- Price/Sales (Trailing 12 Mt.) 30.48
- Price/Book (Most Recent Quarter) 14.57
- Enterprise Value Revenue 21.21
- Enterprise Value EBITDA 45.78
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 59%
- Return on Assets 14%
- Return on Equity 33%
- Earnings Per Share $0.20
- Revenue Per Share $0
- Gross Profit 30.39 million
- Quarterly Earnings Growth 57.9%
View More
Highlights
- Market Capitalization 1.06 billion
- Book Value Per Share $0.61
View More
Share Statistics
- Shares Outstanding 49.41 million
- Shares Float 35.19 million
- % Held by Insiders <1%
View More
Technicals
- Beta 0.53
- 52 Week High $21.24
- 52 Week Low $8.87
- 50 Day Moving Average 17.4
- 200 Day Moving Average 16.36
View More
Dividends
- Forward Annual Dividend Rate $0.02
- Forward Annual Dividend Yield 0.09%
- Payout Ratio 9%
- Dividend Date 2020-09-28
- ExDividend Date 2020-09-04
- Dividend Per Share $0.02
- Dividend Yield 0%
View More
Clinuvel Pharmaceuticals Limited (CLVLY) Dividend Calendar:
CLVLY's last dividend payment was made to shareholders on September 28, 2020.
Clinuvel Pharmaceuticals Limited pays out 9% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Clinuvel Pharmaceuticals Limited (CLVLY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $0.05 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $0.05 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $0.11 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $4.99 million | $0.10 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $4.99 million | $0.00 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $11.03 million | $0.00 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $11.03 million | $0.10 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $552169.38 | $0.10 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $4.49 million | $0.03 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $6.73 million | $0.03 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $7.01 million | $0.09 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $3.53 million | $0.09 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $3.53 million | $0.01 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $4.94 million | $0.01 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $4.94 million | $0.04 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $3.44 million | $0.04 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $3.44 million | $0.02 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.02 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.00 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.00 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.03 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.03 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.03 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.03 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.07 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.08 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.03 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.03 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.04 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.04 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.03 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.04 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.06 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.06 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.06 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.06 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.10 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.10 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.12 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.11 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.08 | $0.00 |
Clinuvel Pharmaceuticals Limited (CLVLY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | N/A | N/A |
| Selling General Administrative | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Income Tax Expense | -338250 | -338250 | -1.76 million | -1.76 million | -1.76 million |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | N/A |
| Net Income Applicable to Common Shares | 3.24 million | 3.24 million | 7.79 million | 7.79 million | 7.79 million |
Cash Flow:
| Date | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -1.22 million | -1.22 million | -1.22 million | -1.22 million | N/A |
| Total Cash Flow from Investing Activities | -341324 | -341324 | -341324 | -341324 | -103089 |
| Net Borrowings | -56614 | -56614 | -56614 | -56614 | -65057 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | -677068 |
| Change to Operating Activities | 382570 | 382570 | 382570 | 382570 | N/A |
| Change in Cash | N/A | N/A | N/A | N/A | 1.58 million |
| Total Cash from Operating Activities | 4.72 million | 4.72 million | 4.72 million | 4.72 million | 2.37 million |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -9251 | -9251 | -9251 | -9251 | N/A |
| Change to Net Income | -1.64 million | -1.64 million | -1.64 million | -1.64 million | 1.84 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 103089 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | N/A |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | 73.67 million | N/A |
| Total Assets | N/A | N/A | N/A | N/A | N/A |
| Common Stock | 151.85 million | 151.85 million | 151.85 million | N/A | 151.85 million |
| Other Current Assets | N/A | N/A | N/A | 151.85 million | N/A |
| Retained Earnings | -76.37 million | -76.37 million | -80.04 million | -80.04 million | -80.04 million |
| Other Liabilities | 72424 | 72424 | 105727 | 105727 | 105727 |
| Other Assets | 4.49 million | 4.49 million | 3.81 million | 3.81 million | 3.81 million |
| Cash | N/A | N/A | N/A | 66.75 million | N/A |
| Total Current Liabilities | 8.59 million | 8.59 million | N/A | 6.66 million | N/A |
| Other Stockholder Equity | 2.61 million | 2.61 million | 1.86 million | 1.86 million | 1.86 million |
| Property, Plant & Equipment | 2.92 million | 2.92 million | 2.39 million | 2.39 million | 2.39 million |
| Total Current Assets | 80.29 million | 80.29 million | N/A | 75.16 million | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 77.9 million | 77.9 million | 73.48 million | 73.48 million | 73.48 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 1.32 million | 1.32 million | N/A | 1.29 million | N/A |
| Accounts Payable | 4.99 million | 4.99 million | N/A | 1.43 million | N/A |
Clinuvel Pharmaceuticals Limited (CLVLY) Chart:
Clinuvel Pharmaceuticals Limited (CLVLY) News:
Below you will find a list of latest news for Clinuvel Pharmaceuticals Limited (CLVLY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Clinuvel Pharmaceuticals Limited (CLVLY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Clinuvel Pharmaceuticals Limited (CLVLY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|